Viva Biotech Holdings disclosed a fresh on-market share repurchase of 1.00 million ordinary shares on 24 June 2026, paying an average HK$1.1180 per share (high: HK$1.13; low: HK$1.11). The transaction cost the company HK$1.12 million.

The buy-back leaves Viva Biotech’s issued share capital unchanged at 2.10 billion shares as of 24 June 2026 because the repurchased shares have not yet been cancelled. Cumulatively, 5.99 million shares acquired between 8 and 24 June 2026 remain pending cancellation, equivalent to 0.28 % of the current issued share base.

Under the shareholder mandate granted on 12 June 2025, Viva Biotech is authorised to repurchase up to 212.84 million shares. To date, 31.30 million shares have been repurchased, utilising 1.47 % of the authorised limit, leaving capacity for a further 181.54 million shares.

In accordance with Hong Kong Stock Exchange rules, the company is subject to a 30-day moratorium on new share issues or treasury share sales following the latest repurchase, ending on 24 July 2026.

All repurchases have been executed in compliance with the HKEX Main Board Listing Rules, and the board has confirmed receipt of all funds related to the transactions.